Tirzepatide reconstitution calculator

Enter your vial amount and target dose. DrawDose returns the BAC water volume, syringe units, and a vial label you can copy.

Quick answer for the most common vial sizes

The 1 mL : 10 mg ratio documented across compounding pharmacy formulation guides and community protocol references for tirzepatide produces a clean 25-units-per-2.5mg relationship at every titration step.

The math holds at any concentration. The 1:10 ratio is convention, not requirement. DrawDose accepts any vial size and any BAC water volume and returns the correct syringe draw for the dose entered.

How to reconstitute lyophilized tirzepatide

The procedure follows the standard sterile-injection prep workflow documented in compounding pharmacy formulation guides and peptide stability literature.

Bring the vial and BAC water to room temperature for 15 to 20 minutes before mixing. Cold liquid hitting cold powder slows dissolution and increases the chance of clumping, per the lyophilized-peptide reconstitution literature.

Wipe both vial tops with an alcohol swab and let them dry. Draw the BAC water into a 1 mL syringe. Insert the needle into the tirzepatide vial at an angle so the water runs down the inside wall, not directly onto the powder pellet — direct impingement on lyophilized peptide generates foam and can denature the protein.

Once the water is in, swirl the vial gently for 20 to 30 seconds. Do not shake. Tirzepatide dissolves quickly and clearly when properly reconstituted; cloudiness that does not clear within a minute indicates either incomplete dissolution or a sourcing concern with the vial.

Why concentration determines syringe units, not vial size

The relationship between vial size, BAC water, and syringe draw is fixed by concentration math, not by the vial label. A 10 mg vial with 1 mL of water gives 10 mg/mL, where every 25 units delivers 2.5 mg. The same 10 mg vial with 2 mL of water gives 5 mg/mL, where 25 units delivers 1.25 mg. To hit a 2.5 mg target dose with the second mix, the draw is 50 units instead of 25.

Standard reconstitution practice keeps the draw between 10 and 50 units on a 1 mL insulin syringe. That's the range where the tick marks are visually distinct and minor variation in the draw doesn't materially change the delivered dose. DrawDose computes this automatically; the auto-selected BAC water volume on the result panel is always tuned to keep the draw in that band.

FDA-approved titration schedule

Per the Mounjaro and Zepbound prescribing information published by Eli Lilly and Company, tirzepatide is administered as a once-weekly subcutaneous injection. The label-specified titration is four weeks at each dose level before increasing.

Weeks 1 to 4: 2.5 mg once weekly. Per the prescribing information, this is a starting dose intended for treatment initiation, not for glycemic control or weight management efficacy.

Weeks 5 to 8: 5 mg once weekly. Per the SURPASS and SURMOUNT trial data referenced in the label, this is the first dose with documented therapeutic effect.

Weeks 9 onward: titration in 2.5 mg increments every four weeks as tolerated, to a maximum of 15 mg once weekly. Intermediate steps are 7.5 mg, 10 mg, and 12.5 mg.

The label specifies that if a patient does not tolerate a dose increase, the manufacturer recommends returning to the previous tolerated dose. The half-life of tirzepatide is approximately 5 days per the prescribing information, which is what enables the once-weekly dosing schedule.

Community protocols: slow titration and microdosing

Survey data aggregated from r/Tirzepatide, r/CompoundedTirzepatide, and r/Mounjaro, alongside compounded-pharmacy protocol literature, describes two titration patterns that exist in compounded-vial practice but are not present in the FDA-approved label.

Slow titration extends each step from the label's 4 weeks to 6 or 8 weeks. The pattern is documented among users with persistent gastrointestinal effects or those who reach a comfortable dose and prefer extended adaptation before climbing. Reaching 10 mg takes 17 to 25 weeks instead of the 13 weeks the label produces.

Microdosing starts below 2.5 mg, often at 0.25 to 1.5 mg, with step-ups over 4 to 8 weeks before joining the standard 2.5 mg starting line. There is no published clinical trial data on tirzepatide doses below 2.5 mg. Compounded pharmacies that offer sub-2.5 mg formulations describe microdosing as off-label adaptation; FDA-aligned prescribing literature treats sub-label doses as untested rather than as an alternative protocol. The honest framing is that the safety and efficacy profile of doses below 2.5 mg is unknown, not known-safe.

The reconstitution math is unaffected by which titration pattern is followed. DrawDose accepts any target dose and returns the unit draw at the chosen concentration.

Adverse reactions per FDA labeling

Per the Mounjaro and Zepbound prescribing information, the most common adverse reactions reported in pivotal clinical trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. Frequency was dose-dependent, with higher rates at the higher titration steps.

Community survey data layers temporal patterns on top of the label's frequency data. Nausea is most commonly reported within 24 to 72 hours of each dose increase, with adaptation typically occurring within two weeks at any given step. Constipation appears in week 2 to 3 of each dose level. Acid reflux is described in user reports as dose-dependent and concentration-related; some users find that stepping back rather than continuing forward resolves it.

Sulfur burps (eructation with a characteristic sulfur taste) are documented in the prescribing information as a manifestation of delayed gastric emptying, which is one of the mechanisms by which tirzepatide produces satiety. Forum-aggregated user reports describe famotidine as commonly used for symptomatic management, though no randomized data confirms the practice.

Fatigue is not listed among the most common adverse reactions in the FDA label. Forum reports attribute it to inadequate protein and electrolyte intake at lower calorie levels rather than to the peptide directly.

Common reconstitution errors

Compounded peptide forums and pharmacy QA literature document a recurring set of errors specific to the user-reconstituted vial workflow.

Drawing the next dose immediately after injection. The water that fills the empty space pulls peptide solution with it, producing inconsistent doses across the vial. Standard practice is to draw the next dose before injecting.

Switching vial sizes mid-protocol without recalculating. A 5 mg vial and a 10 mg vial reconstituted with the same BAC water volume produce different concentrations. The math has to be run fresh for each vial.

Storing reconstituted tirzepatide in the refrigerator door. Door-mounted storage cycles through significant temperature variation each time the door opens. The back of the main compartment is the documented recommendation in peptide stability literature.

Trusting the vial label over the Certificate of Analysis. Compounded vials run 5 to 15% off label in industry-published variance data. The COA reports the actual measured peptide content per the lot's HPLC and mass spec assays, and is the input the calculator should receive.

Storage and shelf life

Per peptide stability literature, reconstituted tirzepatide stays stable for 4 to 6 weeks at 2 to 8°C (36 to 46°F). The benzyl alcohol preservative in bacteriostatic water is what enables this; sterile water without preservative produces a 24-hour shelf life from first puncture.

Lyophilized tirzepatide stores for 18 months or longer at -20°C and 12 months or longer at 2 to 8°C, per the same stability literature. Heat exposure during shipping is the most documented threat to potency. Orders placed in summer months commonly arrive with insulated cold packs.

What to verify on a Certificate of Analysis

The COA reports the actual peptide content of a specific lot. Net peptide weight is the measured milligrams of peptide in the vial, separate from any excipients (sugars, mannitol) included for stability. Purity by HPLC reflects the percentage of UV-absorbing material that is the target peptide; 95% is the research-grade minimum the peptide industry has converged on, 98% is the standard most reputable vendors publish for sensitive applications, and 99% is reserved for reference-standard or publication-grade material. Below 95%, a meaningful fraction of fragments and degradation products is present, with documented potential for reduced potency and unpredictable side effect profiles.

Mass spec confirmation matches the expected molecular weight (4,813.5 Da for tirzepatide) and verifies the molecule is tirzepatide rather than a similar peptide mislabeled. Vendors that decline to share a COA on request are flagged in community sourcing reviews as a quality concern.

Documented combinations

Combination protocols are reported in compounded-pharmacy literature and community surveys; none have published FDA-aligned trial data as combinations.

Tirzepatide plus cagrilintide is the most commonly documented pairing. Cagrilintide is a long-acting amylin analogue that addresses appetite via a separate hormonal mechanism. Combination-vial formulations exist; user reports also describe administering them as separate injections.

Retatrutide, a triple agonist, is described in some user reports as a successor protocol rather than a co-administered compound. Most documented switches go in one direction at a time rather than running stacked.

Tirzepatide combined with semaglutide is not documented as a stable practice. Both are GLP-1 receptor agonists; pharmacological literature describes receptor saturation from co-administration, with the side effect load of two compounds and the efficacy of one.

FAQ

How long does tirzepatide take to start working?

Per the SURPASS and SURMOUNT trial data referenced in the prescribing information, appetite suppression typically appears within 48 hours of the first dose. Meaningful weight reduction begins around week 4 to 6, after the first titration up to 5 mg.

Can a weekly dose be split into two injections?

The Mounjaro and Zepbound labels specify once-weekly dosing. Some users in community protocol surveys report twice-weekly dosing at half the weekly amount to flatten side effect peaks. The total weekly milligrams is the same; the practice is off-label.

Does tirzepatide need to be injected at the same time each week?

Per the prescribing information, the day of administration may be changed if necessary, as long as the time between two doses is at least 3 days (72 hours). Consistency simplifies tracking; rigid timing is not required.

Can reconstituted tirzepatide be frozen?

Peptide stability literature does not support freezing reconstituted tirzepatide. Freeze-thaw cycles damage peptide structure. Volume in excess of 6 weeks of dosing is better stored as additional unreconstituted vials at -20°C, mixed as needed.

What does the label say about a missed dose?

Per the Mounjaro and Zepbound prescribing information, if it has been less than 4 days since the missed dose, take it as soon as remembered. If more than 4 days have passed, skip and resume on the next scheduled day. Doubling up is not recommended. The half-life of approximately 5 days means a single late dose rarely affects steady-state levels significantly.

Is microdosing tirzepatide safe?

There is no published clinical trial data on tirzepatide doses below 2.5 mg. Some compounded pharmacies offer sub-2.5 mg formulations, and prescribers use them off-label for users sensitive to gastrointestinal effects. The safety and efficacy profile at sub-label doses is unknown rather than known-safe.